TRADE NEWS: Agilent Technologies Launches New Products for Analyzing Biotherapeutics
June 23 2015 - 11:00AM
Business Wire
Expanded AdvanceBio Portfolio Enables
Scientists to Speed Research and Lower Costs
Agilent Technologies Inc. (NYSE:A) today announced two additions
to its AdvanceBio product family, designed to provide rapid,
reproducible results for scientists in the biopharmaceutical
industry.
Agilent introduced the products—the AdvanceBio glycan-mapping
workflow and the AdvanceBio oligonucleotide column—at HPLC 2015, an
international symposium being held in Geneva, Switzerland,
this week.
“Both of these new products will help researchers achieve
faster, more reliable separations, lowering their cost per
analysis,” said Helen Stimson, Agilent vice president and general
manager of the Chemistries and Supplies Division. “Like all
AdvanceBio solutions, they are designed to deliver results that are
easy to reproduce, increasing confidence in their accuracy and
completeness—vital aspects of biopharmaceutical development.”
The company’s new AdvanceBio glycan-mapping workflow is a
complete consumables workflow for deglycosylation, 2-AB labeling
and HILIC glycan analysis using mass spectrometry and fluorescence
detection. This unique workflow features AdvanceBio glycan-mapping
columns, glycan standards and N-glycan sample-preparation kits,
along with all the consumable components researchers require.
The product’s comprehensive guides and standard methods provide
researchers with everything they need to quickly identify and
quantify glycans in a way that is easily reproducible.
The new AdvanceBio oligonucleotide column is the first high-pH,
stable, superficially porous particle-based liquid chromatography
column for oligonucleotide analysis. It builds on Agilent’s
innovations in superficially porous silica-based columns for
biomolecule separations, which began with the Poroshell 300 in 2001
and includes AdvanceBio peptide-mapping, glycan-mapping and RP-mAb
columns.
The right particle design gives researchers the flexibility to
use high-performance or ultra-high-performance liquid
chromatography systems. The increased flexibility also allows them
to make more efficient use of existing laboratory resources, thus
reducing costs.
AdvanceBio oligonucleotide columns and oligonucleotide standards
improve the reliability of results and reduce costs for therapeutic
oligonucleotide analysis.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in
life sciences, diagnostics and applied chemical markets, is the
premier laboratory partner for a better world. Agilent works with
customers in more than 100 countries, providing instruments,
software, services and consumables for the entire laboratory
workflow. The company generated revenues of $4.0 billion in fiscal
2014 and employs about 12,000 people worldwide. Agilent marks its
50th anniversary in analytical instrumentation this year.
Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and
executive news is available at www.agilent.com/go/news.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150623005380/en/
Agilent Technologies Inc.Victoria Wadsworth-Hansen, +1
408-553-2005victoria.wadsworth-hansen@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024